These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26055638)

  • 1. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.
    Harris AW; Butchbach ME
    Neuromuscul Disord; 2015 Sep; 25(9):699-705. PubMed ID: 26055638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.
    Butchbach ME; Singh J; Gurney ME; Burghes AH
    Exp Neurol; 2014 Jun; 256():1-6. PubMed ID: 24681157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.
    Butchbach ME; Singh J; Thorsteinsdóttir M; Saieva L; Slominski E; Thurmond J; Andrésson T; Zhang J; Edwards JD; Simard LR; Pellizzoni L; Jarecki J; Burghes AH; Gurney ME
    Hum Mol Genet; 2010 Feb; 19(3):454-67. PubMed ID: 19897588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.
    Rose FF; Mattis VB; Rindt H; Lorson CL
    Hum Mol Genet; 2009 Mar; 18(6):997-1005. PubMed ID: 19074460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H; Buckley DM; Vale SM; Krogman M; Rose FF; Garcia ML; Lorson CL
    Neuromuscul Disord; 2012 Mar; 22(3):277-85. PubMed ID: 22079083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DcpS inhibitor RG3039 improves motor function in SMA mice.
    Van Meerbeke JP; Gibbs RM; Plasterer HL; Miao W; Feng Z; Lin MY; Rucki AA; Wee CD; Xia B; Sharma S; Jacques V; Li DK; Pellizzoni L; Rusche JR; Ko CP; Sumner CJ
    Hum Mol Genet; 2013 Oct; 22(20):4074-83. PubMed ID: 23727836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
    Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
    El-Khodor BF; Edgar N; Chen A; Winberg ML; Joyce C; Brunner D; Suárez-Fariñas M; Heyes MP
    Exp Neurol; 2008 Jul; 212(1):29-43. PubMed ID: 18455159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.
    Gogliotti RG; Cardona H; Singh J; Bail S; Emery C; Kuntz N; Jorgensen M; Durens M; Xia B; Barlow C; Heier CR; Plasterer HL; Jacques V; Kiledjian M; Jarecki J; Rusche J; DiDonato CJ
    Hum Mol Genet; 2013 Oct; 22(20):4084-101. PubMed ID: 23736298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor neuron pathology and behavioral alterations at late stages in a SMA mouse model.
    Fulceri F; Bartalucci A; Paparelli S; Pasquali L; Biagioni F; Ferrucci M; Ruffoli R; Fornai F
    Brain Res; 2012 Mar; 1442():66-75. PubMed ID: 22306031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.
    Cherry JJ; DiDonato CJ; Androphy EJ; Calo A; Potter K; Custer SK; Du S; Foley TL; Gopalsamy A; Reedich EJ; Gordo SM; Gordon W; Hosea N; Jones LH; Krizay DK; LaRosa G; Li H; Mathur S; Menard CA; Patel P; Ramos-Zayas R; Rietz A; Rong H; Zhang B; Tones MA
    PLoS One; 2017; 12(9):e0185079. PubMed ID: 28945765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
    Shababi M; Glascock J; Lorson CL
    Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
    See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
    Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA.
    Iyer CC; McGovern VL; Murray JD; Gombash SE; Zaworski PG; Foust KD; Janssen PM; Burghes AH
    Hum Mol Genet; 2015 Nov; 24(21):6160-73. PubMed ID: 26276812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.
    Monani UR; Pastore MT; Gavrilina TO; Jablonka S; Le TT; Andreassi C; DiCocco JM; Lorson C; Androphy EJ; Sendtner M; Podell M; Burghes AH
    J Cell Biol; 2003 Jan; 160(1):41-52. PubMed ID: 12515823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
    Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.